Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
1.
Int Endod J ; 2024 Jun 12.
Artículo en Inglés | MEDLINE | ID: mdl-38864596

RESUMEN

AIM: Apical periodontitis (AP) is the chronic inflammation of the periradicular tissues in response to root canal infection. Whilst AP has been linked with systemic inflammation and noncommunicable diseases, its potential association with nonalcoholic fatty liver disease (NAFLD) is unknown. We aimed to evaluate the serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels as surrogate markers of hepatic injury, and the systemic inflammatory burden in otherwise healthy individuals with and without AP diagnosis. METHODOLOGY: Cross-sectional study. Individuals with AP (n = 30) and healthy controls (n = 29) were recruited. The number, mean diameter (mm) and periapical index of the apical lesions of endodontic origin (ALEO) were assessed. ALT and AST levels (pg/mL) were measured through enzyme-linked immunosorbent assays. The serum levels of TNF-α, IL-4, IL-9, IL-10, IL-17A and IL-22 were evaluated by Multiplex assay. Inferential analysis was performed using t-test or Mann-Whitney tests according to data distribution and linear regression models. Data were analysed with StataV16 (p < .05). RESULTS: ALT and AST levels were significantly higher in individuals with AP compared to controls (p < .05). Serum inflammatory biomarkers showed no significant differences between the study groups. Bivariate and multivariate analyses confirmed that AP diagnosis was independently associated with ALT and AST elevations (p < .05). Additionally, the number of ALEO positively influenced AST levels (p = .002). IL-22 on the other hand, was associated with reduced ALT levels (p = .043). CONCLUSION: AP is associated with higher serum hepatic transaminases ALT and AST, potentially contributing to NAFLD physiopathology in young adults.

2.
GE Port J Gastroenterol ; 31(3): 173-181, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38757065

RESUMEN

Introduction: Autoimmune hepatitis (AIH) has a spectrum of symptoms ranging from asymptomatic disease to acute severe hepatitis, chronic hepatitis, and decompensated cirrhosis. The acute presentation is not rare and could represent genuine acute AIH (GAAIH) or acute exacerbation of chronic autoimmune hepatitis. We aimed to identify the prevalence, clinical features, and prognostic factors associated with GAAIH and compare these cases with acute exacerbation of chronic AIH. Methods: This cross-sectional observational study evaluated patients with acute AIH presentation, defined as total bilirubin >5 times the upper limit of normality (xULN) and/or alanine aminotransferase >10 xULN, and no prior history of liver disease. Histology findings of acute disease defined GAAIH. Bivariate analyses were performed to identify factors associated with the GAAIH, when compared with acute exacerbation of chronic AIH. Results: Seventy-two patients with acute presentation of AIH were included and six (8.3%) of them presented GAAIH. Comparative analysis between patients with GAAIH and patients with acute exacerbation of chronic AIH revealed that prothrombin activity (96% [74-100] vs. 61% [10-100]; p = 0.003) and albumin levels (3.9 ± 0.2 g/dL vs. 3.4 ± 0.5 g/dL; p < 0.001) were higher in patients with GAAIH. The International Autoimmune Hepatitis Group score was higher in patients with acute exacerbation of chronic AIH (18.5 [8-23] vs. 16.5 [15-17]; p = 0.010). Compared to 15.2% of acute exacerbation of chronic AIH, complete therapeutic response to treatment was achieved in 67.7% of cases with GAAIH (p = 0.018). Conclusions: GAAIH was rare (8.3%), and patients with this presentation exhibited more preserved liver function tests, suggesting that most cases presenting with loss of function are acute exacerbation of chronic AIH. Additionally, patients with GAAIH had a better complete therapeutic response, suggesting a more preserved liver function at presentation, and early diagnosis has a positive therapeutic implication.


Introdução: A hepatite autoimune (HAI) apresenta um espectro de sintomas que varia de doença assintomática a hepatite aguda grave, hepatite crónica e cirrose descompensada. A apresentação aguda não é rara e pode representar hepatite autoimune aguda genuína (HAIAG) ou exacerbação aguda de hepatite autoimune crónica (EAHAIC). O nosso objetivo foi identificar a prevalência, caraterísticas clínicas e fatores prognósticos associados à HAIAG, e comparar esses casos com EAHAIC. Métodos: Estudo observacional, transversal, incluindo doentes com apresentação aguda de HAI, definida como bilirrubina total > 5 vezes o limite superior da normalidade (xLSN) e/ou ALT > 10 xLSN, e sem história prévia de doença hepática. HAIAG foi definida pela presença de achados histológicos de doença aguda. Análises bivariadas foram realizadas para identificar fatores associados à HAIAG, quando comparado com o EAHAIC. Resultados: Foram incluídos setenta e dois doentes com apresentação aguda de HAI, dos quais seis (8.3%) com HAIAG. A análise comparativa entre doentes com HAIAG e doentes com EAHAIC mostrou que a atividade de protrombina (96% (74-100) versus 61% (10-100; p=0.003) e os níveis de albumina (3,9 ± 0,2 g/dL vs. 3,4 ± 0,5 g/dL; p < 0,001) foram significativamente mais elevados em pacientes com HAIAG. O score do Grupo Internacional de Hepatite Autoimune foi mais elevado em doentes com EAHAIC (18.5 (8-23) versus 16.5 (15-17); p=0.010). A resposta terapêutica completa ao tratamento foi alcançada em 66.7% dos casos de HAIAG (vs. 15,2% na EAHAIC, p=0,018). Conclusões: A HAIAG é rara (8.3%), e os doentes com esta apresentação mostraram testes de função hepática mais preservados, sugerindo que a maioria dos casos com perda de função são EAHAIC. Além disso, os doentes com HAIAG tiveram maior taxa de resposta terapêutica completa, sugerindo que uma função hepática mais preservada na apresentação e o diagnóstico precoce tem uma implicação terapêutica positiva.

3.
Artículo en Español | LILACS-Express | LILACS | ID: biblio-1560463

RESUMEN

Introducción: las enzimas y marcadores del perfil hepático permiten evaluar la funcionalidad y condición del hígado. Sus elevaciones pueden ser silentes y con cierta prevalencia en muchos adultos. Objetivo: determinar las principales alteraciones en el hepatograma en pacientes que acuden a consulta médica de rutina. Metodología: estudio descriptivo, prospectivo y transversal realizado a partir de resultados de laboratorio de historias clínicas de 364 pacientes de todas las edades y ambos sexos pertenecientes a un policlínico del distrito de Villa el Salvador, Perú desde enero de 2021 a julio de 2022. Las variables fueron: edad, sexo, valores de transaminasa glutámico pirúvica (TGP), transaminasa glutámico oxalacética (TGO), bilirrubina directa, indirecta y total, albúmina, globulinas y fosfatasa alcalina (FA). Resultados: en el promedio total de la muestra, la TGP fue alta (51,05 U/L), así como la bilirrubina total (1,50 mg/dL) y la FA (135,84 U/L). La TGP fue alta en hombres (54,92 U/L) y mujeres (48,86 U/L). La TGO fue normal en mujeres y alta en hombres (48,24 U/L). La bilirrubina indirecta fue alta en hombres (1,33 mg/dL). La FA fue más alta en ambos sexos (143,28 U/L en hombres y 126,38 en mujeres). Según grupo etario, los valores de TGO fueron más altos en el grupo de edad igual o mayor a 40 años (49,99 U/L). Los valores de TGP fueron elevados en ambos sexos (55,96 U/L en hombres y 50,90 U/L en mujeres), así como en la bilirrubina total, la que fue más alta en el grupo de edad igual o mayor a 40 años (2,03 mg/dL). La bilirrubina indirecta, albúmina y FA fueron normales en el grupo de edad igual o menor de 39 años, pero fueron elevadas en el grupo de edad igual o mayor a 40 años (1,13 mg/dL, 5,77 gr/dL y 147,95 U/L, respectivamente). Conclusiones: existen alteraciones en el perfil hepático en pacientes asintomáticos en la muestra estudiada. A pesar de no ser elevaciones significativamente grandes, se recomienda identificar y tratar las posibles causas que pudieran desencadenar dichas elevaciones, así como la realización de más estudios similares a nivel nacional para caracterizar el perfil hepático de nuestra población.


Introduction: The enzymes and markers of the liver profile allow us to evaluate the functionality and condition of the liver. Their elevations may be silent and have a certain prevalence in many adults. Objective: To determine the main alterations in the hepatogram in patients who attend routine medical consultation. Methodology: Descriptive, prospective and cross-sectional study carried out based on laboratory results from medical records of 364 female and male patients of all ages attending a polyclinic in the district of Villa El Salvador, Peru from January 2021 to July 2022. The variables were: age, sex, values ​​of alanine aminotransferase (ALT), aspartate transaminase (AST), direct, indirect and total bilirubin, albumin, globulins and alkaline phosphatase (ALP). Results: In the total average of the sample, ALT was high (51.05 U/L), as well as total bilirubin (1.50 mg/dL) and ALP (135.84 U/L). ALT was high in men (54.92 U/L) and women (48.86 U/L) while AST was normal in women and high in men (48.24 U/L). Indirect bilirubin was high in men (1.33 mg/dL) and ALP was higher in both sexes (143.28 U/L in men and 126.38 in women). According to age group, AST values ​​were highest in the age group equal to or greater than 40 years (49.99 U/L). ALT values ​​were high in both sexes (55.96 U/L in men and 50.90 U/L in women), as well as total bilirubin, which was highest in the age group equal to or greater than 40 years (2.03 mg/dL). Indirect bilirubin, albumin and ALP were normal in the age group equal to or less than 39 years, but were elevated in the age group equal to or greater than 40 years (1.13 mg/dL, 5.77 gr/dL and 147.95 U/L, respectively). Conclusions: There are alterations in the liver profile of asymptomatic patients in the sample studied. Although they are not significantly large elevations, it is recommended to identify and treat the possible causes that could trigger these elevations, as well as carrying out more similar studies at a national level to characterize the liver profile of our population.

4.
Artículo en Español | LILACS-Express | LILACS | ID: biblio-1522894

RESUMEN

Introducción: la alanina aminotransferasa es un nexo importante en el metabolismo de aminoácidos y carbohidratos, asimismo es un marcador de inflamación hepática. Estudios previos mostraron la relación entre la diabetes mellitus y esta enzima bajo diferentes contextos clínicos. Objetivo: evaluar la correlación entre glucosa basal y alanina aminotransferasa tanto en pacientes con diabetes mellitus tipo 2 como sin ella. Metodología: estudio observacional, analítico y transversal realizado desde enero de 2021 a junio de 2022 con una población de 566 pacientes dividida en grupos con diabetes mellitus tipo 2 (n 224) y sin diabetes mellitus tipo 2 (n 342). Fueron incluidos los pacientes de edad igual o mayor a 18 años con y sin diabetes mellitus tipo 2. Se excluyó a pacientes con patologías múltiples y/o con diagnóstico de diabetes inferior a 6 meses. Se realizó el análisis inferencial con la prueba de correlación de Spearman y la prueba de normalidad de Kolmogorov-Smirnov. Los datos fueron procesados con el software SPSS statistics 25™. Resultados: la correlación entre glucosa y alanina aminotransferasa en sujetos sin diabetes fue 0,212 (p=0,003) y la correlación entre glucosa y alanina aminotransferasa en aquellos con diabetes fue -0,434 (p=0,015). Conclusiones: la alanina aminotransferasa se relaciona con mayor intensidad en pacientes con diabetes mellitus tipo 2 que en aquellos sin diabetes. La correlación moderada y negativa en sujetos con diabetes mellitus tipo 2 indicaría alteraciones en la interacción entre la alanina aminotransferasa y la glucosa en los que la hiperglucemia sostenida tendría un papel relevante, probablemente por un incremento en la actividad de transaminación.


Introduction: Alanine aminotransferase is an important nexus in the metabolism of amino acids and carbohydrates, and is also a marker of liver inflammation. Previous studies showed the relationship between diabetes mellitus and this enzyme under different clinical contexts. Objective: To evaluate the correlation between basal glucose and alanine aminotransferase both in patients with and without type 2 diabetes mellitus. Methodology: Observational, analytical, and cross-sectional study conducted from January 2021 to June 2022 with a population of 566 patients divided into groups with type 2 diabetes mellitus (n 224) and without it (n 342). Patients aged 18 years or older with and without type 2 diabetes mellitus were included. Patients with multiple pathologies and/or diagnosed with diabetes less than 6 months were excluded. Inferential analysis was performed with Spearman's correlation test and the Kolmogorov-Smirnov normality test. The data was processed with the SPSS statistics 25™ software. Results: The correlation between glucose and alanine aminotransferase in subjects without diabetes was 0.212 (p=0.003) and the correlation between glucose and alanine aminotransferase in those with diabetes was -0.434 (p=0.015). Conclusions: Alanine aminotransferase is associated with greater intensity in patients with type 2 diabetes mellitus than in those without diabetes. The moderate and negative correlation in subjects with type 2 diabetes mellitus would indicate alterations in the interaction between alanine aminotransferase and glucose in which sustained hyperglycemia would play a relevant role, probably due to an increase in transamination activity.

5.
Rev. bras. cir. cardiovasc ; Rev. bras. cir. cardiovasc;37(6): 829-835, Nov.-Dec. 2022. tab
Artículo en Inglés | LILACS-Express | LILACS | ID: biblio-1407311

RESUMEN

ABSTRACT Introduction: Infective endocarditis is a disease that progresses with morbidity and mortality, afecting 3-10 out of 100,000 people per year. We conducted this study to review the early outcomes of surgical treatment of infective endocarditis. Methods: In this retrospective study, 122 patients who underwent cardiac surgery for infective endocarditis in our clinic between November 2009 and December 2020 were evaluated. Patients were divided into two groups according to in-hospital mortality. Demographic, echocardiographic, laboratory, operative, and postoperative data of the groups were compared. Results: Between November 3, 2009, and December 7, 2020, 122 patients were operated for infective endocarditis in our hospital. Emergency surgery was performed in nine (7.3%) patients. In-hospital mortality occurred in 23 (18.9%) patients, and 99 (81.1%) patients were discharged. In-hospital mortality was related with older age, presence of periannular abscess, New York Heart Association class 3 or 4 symptoms, low albumin level, high alanine aminotransferase level, and longer cross-clamping time (P<0.05 for all). Conclusion: The presence of paravalvular abscess was the most important prognostic factor in patients operated for infective endocarditis.

6.
Braz J Cardiovasc Surg ; 37(6): 829-835, 2022 12 01.
Artículo en Inglés | MEDLINE | ID: mdl-36259995

RESUMEN

INTRODUCTION: Infective endocarditis is a disease that progresses with morbidity and mortality, afecting 3-10 out of 100,000 people per year. We conducted this study to review the early outcomes of surgical treatment of infective endocarditis. METHODS: In this retrospective study, 122 patients who underwent cardiac surgery for infective endocarditis in our clinic between November 2009 and December 2020 were evaluated. Patients were divided into two groups according to in-hospital mortality. Demographic, echocardiographic, laboratory, operative, and postoperative data of the groups were compared. RESULTS: Between November 3, 2009, and December 7, 2020, 122 patients were operated for infective endocarditis in our hospital. Emergency surgery was performed in nine (7.3%) patients. In-hospital mortality occurred in 23 (18.9%) patients, and 99 (81.1%) patients were discharged. In-hospital mortality was related with older age, presence of periannular abscess, New York Heart Association class 3 or 4 symptoms, low albumin level, high alanine aminotransferase level, and longer cross-clamping time (P<0.05 for all). CONCLUSION: The presence of paravalvular abscess was the most important prognostic factor in patients operated for infective endocarditis.


Asunto(s)
Endocarditis Bacteriana , Endocarditis , Prótesis Valvulares Cardíacas , Humanos , Absceso/cirugía , Estudios Retrospectivos , Endocarditis Bacteriana/complicaciones , Endocarditis Bacteriana/cirugía , Endocarditis/cirugía , Mortalidad Hospitalaria
7.
Ann Hepatol ; 19(6): 627-634, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32882393

RESUMEN

INTRODUCTION AND OBJECTIVES: The novel coronavirus disease 2019 (COVID-19) has affected more than 5 million people globally. Data on the prevalence and degree of COVID-19 associated liver injury among patients with COVID-19 remain limited. We conducted a systematic review and meta-analysis to assess the prevalence and degree of liver injury between patients with severe and non-severe COVID-19. METHODS: We performed a systematic search of three electronic databases (PubMed/MEDLINE, EMBASE and Cochrane Library), from inception to 24th April 2020. We included all adult human studies (>20 subjects) regardless of language, region or publication date or status. We assessed the pooled odds ratio (OR), mean difference (MD) and 95% confidence interval (95%CI) using the random-effects model. RESULTS: Among 1543 citations, there were 24 studies (5961 subjects) which fulfilled our inclusion criteria. The pooled odds ratio for elevated ALT (OR = 2.5, 95%CI: 1.6-3.7, I2 = 57%), AST (OR = 3.4, 95%CI: 2.3-5.0, I2 = 56%), hyperbilirubinemia (OR = 1.7, 95%CI: 1.2-2.5, I2 = 0%) and hypoalbuminemia (OR = 7.1, 95%CI: 2.1-24.1, I2 = 71%) were higher subjects in critical COVID-19. CONCLUSION: COVID-19 associated liver injury is more common in severe COVID-19 than non-severe COVID-19. Physicians should be aware of possible progression to severe disease in subjects with COVID-19-associated liver injury.


Asunto(s)
Betacoronavirus , Infecciones por Coronavirus/complicaciones , Hepatopatías/epidemiología , Hepatopatías/virología , Neumonía Viral/complicaciones , COVID-19 , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/epidemiología , Humanos , Hepatopatías/diagnóstico , Pandemias , Neumonía Viral/diagnóstico , Neumonía Viral/epidemiología , SARS-CoV-2
8.
Toxicol Rep ; 6: 1182-1187, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31763182

RESUMEN

Byrsonima sericea DC. (Malpighiaceae) leaves are popularly folk medicine in Brazil used to treat gastro-intestinal disorders including diarrhea and gastric diseases. Ethanol extract (BSEE), ethyl acetate extract (BSEAE) and hexane extract (BSHE) of the leaf part of Byrsonima sericea DC were characterized for their total phenolics, proanthocyanidins and flavonoids content. The total antioxidant capacity of extracts was determined. The ethnopharmacological use of B. sericea leaves was evaluated by assaying BSEE for gastroprotective activity in stomach ulcer induced by indomethacin, intestinal motility and toxicity. Abundance of phenols mainly tannins was found in BSEE. Total phenolics, flavonoids and proanthocyanidins content in BSEE were found to be 0.371, 0.172 and 1.3 × 10-4 (mg/g) respectively. BSEE showed concentration dependent significant scavenging of DPPH values 90.0 (%) respectively. Moreover, oral doses of 500 and 1000 mg/kg did not cause mortality, and there was no difference in animals weight, organs relative weight and alanine transaminase (ALT) and aspartate transaminase (AST), as compared to the control group. Doses of 250, 500 and 1000 mg/kg inhibited the gastric lesions induced by indomethacin in 52, 60 and 62 % respectively. The dose of 1000 mg/kg decreased intestinal motility in animals. The presence of phenolic compounds, including tannins could be associated with the anti-diarrheal action and the antioxidant properties could collaborate to the gastroprotective and anti- diarrheal activities, confirming its popular use of the plant.

9.
Acta méd. peru ; 36(4): 253-258, oct.-dic 2019. ilus, tab
Artículo en Español | LILACS-Express | LILACS | ID: biblio-1141955

RESUMEN

Objetivo: Evaluar la alanina aminotransferasa (ALT) como marcador en el diagnóstico de síndrome metabólico (SM) y riesgo cardiovascular (RCV) en niños con obesidad exógena. Materiales y métodos: Estudio transversal. Se incluyeron niños con obesidad exógena de 2 a 14 años, atendidos en la Unidad de Endocrinología Pediátrica del Hospital Nacional Cayetano Heredia, entre el 2014 al 2018. Se definió enfermedad hepática no alcohólica (EHNA) considerando dos puntos de corte de ALT; en mujeres: >22,1U/L y >44U/L, en varones: >25,8U/L y >50U/L. Se definió SM según la Academia Americana de Pediatría y RCV con TG/HDL-C ≥3,5. Aplicamos Chi cuadrado, considerándose significativo p<0,05. Estimamos sensibilidad(S), especificidad (E) y likelihood ratios (LR). Resultados: Se incluyeron 347 niños obesos (54,7% varones). La frecuencia de EHNA fue de 23,1%. La sensibilidad y especificidad para el diagnóstico de SM con ALT >22,1U/L y >25,8U/L fue 79,4% y 37,6% respectivamente y, con ALT>44U/L y >50U/L fue 28,6% y 83,3%. La ALT con punto de corte mayor en conjunto con TG/HDL-C≥3,5 mostró una especificidad del 96,9% y un likelihood ratio + (LR+) de 6,7. Conclusión: La ALT con un punto de corte >44U/L en mujeres y >50U/L en varones, es un marcador bioquímico útil en la identificación de SM y riesgo cardiovascular en niños con obesidad exógena desde los primeros años de vida.


Objective: To assess alanine aminotransferase (ALT) as a marker for diagnosing metabolic syndrome (MS) and cardiovascular risk in children with exogenous obesity. Materials and Methods: This is a cross-sectional study. Children with exogenous obesity between 2 and 14 years of age seen in the Pediatric Endocrinology Unit at Cayetano Heredia Hospital between 2014 and 2018 were included. Non alcoholic liver disease was defined considering two ALT cutoff points: >22.1 U/L and >44 U/L in females and >25.8 U/L and >50 U/L in males. MS was defined according to the American Academy of Pediatrics criteria, and cardiovascular risk was defined with TG/HDL-C ratio ³3.5. We used chi-square test, and p<0.05 was deemed as significant. We estimated sensitivity (S), specificity (E) and likelihood ratios (LR). Results: Three-hundred and forty-seven obese children were included (54.7% were male). Non-alcoholic liver disease frequency was 23.1%. Sensitivity and specificity values for diagnosing MS with ALT >22.1 U/L and >25.8 U/L were 79.4% and 37.6%, respectively; and with ALT >44 U/L and 50 U/L these values were 28.6% and 83.3%. ALT levels with higher cutoff values, together with a ³3.5 TG/HDL-C ratio showed 96.9% specificity and 6.7 likelihood ratio (LR+). Conclusion: ALT levels with a >44 U/L cutoff value in females and >50 U/L in males is a useful biochemical marker for identifying MS and determining cardiovascular risk in children with exogen obesity during their early years of life.

10.
Acta cir. bras. ; 34(6): e201900607, Sept. 19, 2019. tab, graf
Artículo en Inglés | VETINDEX | ID: vti-23317

RESUMEN

Purpose: Coleus forskohlii Briq., a medicinal plant originally from India, has been indicated against heart disease, expiratory disorders, convulsions, and hepatic changes, among others. In view of the broad pharmacological potential of the plant and the scarce information about its effects, the objective of the present study was to investigate the effect of its use for pretreatment of partially hepatectomized rats. Methods: The animals were divided into two experimental groups: Control (CG) receiving physiological saline for 10 days before partial hepatetctomy, and Treated (TG) receiving 40 mg Coleus forskohlii/kg/day for 10 days before partial hepatectomy. The treatments were performed by gastric gavage. After the surgical procedure, treatment was continued according to the following groups: CG 24 h, CG 48 h, TG 24 h, and TG 48 hs, and liver tissue and intracardiac blood samples were obtained for histological and biochemical analysis, respectively. Results: No significant differences were observed in mitotic or apoptotic index or in the concentrations of the enzymes AST, ALT and alkaline phosphatase, and no areas of fibrosis were detected. Conclusion: Treatment with Coleus forskohlii did not interfere with the course of hepatic hyperplasia.(AU)


Asunto(s)
Animales , Masculino , Ratas , Hepatopatías/tratamiento farmacológico , Hepatopatías/prevención & control , Hiperplasia/tratamiento farmacológico , Hiperplasia/prevención & control , Hepatectomía/métodos , Coleus/efectos de los fármacos , Hígado/anatomía & histología , Hígado/química , Plantas Medicinales/efectos de los fármacos , Ratas Wistar/cirugía
11.
Acta cir. bras ; Acta cir. bras;34(6): e201900607, 2019. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1019264

RESUMEN

Abstract Purpose Coleus forskohlii Briq., a medicinal plant originally from India, has been indicated against heart disease, expiratory disorders, convulsions, and hepatic changes, among others. In view of the broad pharmacological potential of the plant and the scarce information about its effects, the objective of the present study was to investigate the effect of its use for pretreatment of partially hepatectomized rats. Methods The animals were divided into two experimental groups: Control (CG) receiving physiological saline for 10 days before partial hepatetctomy, and Treated (TG) receiving 40 mg Coleus forskohlii/kg/day for 10 days before partial hepatectomy. The treatments were performed by gastric gavage. After the surgical procedure, treatment was continued according to the following groups: CG 24 h, CG 48 h, TG 24 h, and TG 48 hs, and liver tissue and intracardiac blood samples were obtained for histological and biochemical analysis, respectively. Results No significant differences were observed in mitotic or apoptotic index or in the concentrations of the enzymes AST, ALT and alkaline phosphatase, and no areas of fibrosis were detected. Conclusion Treatment with Coleus forskohlii did not interfere with the course of hepatic hyperplasia.


Asunto(s)
Animales , Masculino , Ratas , Extractos Vegetales/administración & dosificación , Plectranthus/química , Hepatectomía/métodos , Hígado/patología , Aspartato Aminotransferasas/sangre , Biomarcadores/sangre , Hepatocitos/efectos de los fármacos , Alanina Transaminasa/sangre , Fosfatasa Alcalina/sangre , Hiperplasia/tratamiento farmacológico , Hígado/cirugía , Hígado/efectos de los fármacos
12.
Rev. colomb. gastroenterol ; 33(4): 473-477, oct.-dic. 2018. graf
Artículo en Español | LILACS | ID: biblio-985503

RESUMEN

Resumen El albendazol es un medicamento usado para tratar infecciones por helmintos y usualmente presenta pocos o ningún efecto secundario. A pesar de que hay un incremento transitorio de enzimas hepáticas luego de su uso, existe poca evidencia en la literatura en la que se reporte lesión hepática luego de automedicación con albendazol. En este informe, el paciente se presentó con hepatitis aguda luego de automedicarse con albendazol. El paciente cuenta además con una historia de episodios similares después de haber usado el fármaco. Se evaluada la causalidad con el método de evaluación de causalidad de Roussel Uclaf del Concejo para Organizaciones Internacionales de Ciencias Médicas, cuyo resultado fue un puntaje de 10, lo que indicó una alta probabilidad de lesión hepática inducida por albendazol al cabo de realizarse una investigación rigurosa y de excluir otras posibles causas de la condición física del paciente. En conclusión, aunque es ideal agilizar el proceso para combatir a los helmintos, es necesario intensificar la necesidad de monitorizaciones de calidad para evitar reacciones adversas como la hepatitis inducida por medicamentos. Asimismo, la automedicación de cualquier medicamento debe ser siempre evitada.


Abstract Albendazole is used to treat helminth infections and usually has minimal or no side effects. A transient increase in liver enzymes is common following its use, but little evidence of albendazole-induced liver damage has been reported in the literature. This study presents a patient who developed acute hepatitis following self-medication with albendazole. The patient also had a history of similar episodes in the past after using the drug. After a thorough investigation and exclusion of all other causes of the patient's clinical condition, the Roussel Uclaf Causality Assessment Method of the Council for International Organizations of Medical Sciences scale yielded a score of 10 points, indicating a high probability of albendazole-induced liver damage. In conclusion, expediting the process of combating helminths is ideal, but quality monitoring is required to avoid adverse reactions such as drug-induced hepatitis. Moreover, self-medication with any drug should always be discouraged.


Asunto(s)
Humanos , Femenino , Adulto , Albendazol , Enfermedad Hepática Inducida por Sustancias y Drogas , Hepatitis , Automedicación , Efecto Rebote , Helmintos , Hígado
13.
Acta cir. bras. ; 33(5): 439-445, May 2018. ilus, graf
Artículo en Inglés | VETINDEX | ID: vti-734709

RESUMEN

Purpose: To investigate the effects of capsiate treatment on hepatic hyperplasia in partially hepatectomized rats. Methods: The animals were divided into a Capsiate group (CPH), a Capsiate Post-Partial Hepatectomy group (CPPH) and a Partial Hepatectomy Control group (PH). CPH and CPPH animals received 60 mg/kg/day Capsiate for 30 days. Next, the rats underwent partial hepatectomy. CPPH animals continued to receive treatment for 48 h after partial hepatectomy. Liver tissue and intracardiac blood samples were obtained 24 or 48 h after PH. Results: Capsiate treatment interfered with hepatic parameters, reducing the number of mitoses and apoptosis and increasing blood ALT and alkaline phosphatase concentrations. Conclusion: Capsiate treatment preceding hepatic surgery may compromise the initial period of postoperative recovery.(AU)


Asunto(s)
Animales , Masculino , Ratas , Capsaicina/análogos & derivados , Capsaicina/efectos adversos , Capsaicina/uso terapéutico , Hepatectomía/rehabilitación , Periodo Posoperatorio
14.
Acta cir. bras ; Acta cir. bras;33(5): 439-445, May 2018. graf
Artículo en Inglés | LILACS | ID: biblio-949344

RESUMEN

Abstract Purpose: To investigate the effects of capsiate treatment on hepatic hyperplasia in partially hepatectomized rats. Methods: The animals were divided into a Capsiate group (CPH), a Capsiate Post-Partial Hepatectomy group (CPPH) and a Partial Hepatectomy Control group (PH). CPH and CPPH animals received 60 mg/kg/day Capsiate for 30 days. Next, the rats underwent partial hepatectomy. CPPH animals continued to receive treatment for 48 h after partial hepatectomy. Liver tissue and intracardiac blood samples were obtained 24 or 48 h after PH. Results: Capsiate treatment interfered with hepatic parameters, reducing the number of mitoses and apoptosis and increasing blood ALT and alkaline phosphatase concentrations. Conclusion: Capsiate treatment preceding hepatic surgery may compromise the initial period of postoperative recovery.


Asunto(s)
Animales , Masculino , Ratas , Capsaicina/análogos & derivados , Hepatectomía , Hígado/enzimología , Aspartato Aminotransferasas/metabolismo , Capsaicina/farmacología , Ratas Wistar , Apoptosis/efectos de los fármacos , Alanina Transaminasa/metabolismo , Fosfatasa Alcalina/metabolismo , Hígado/efectos de los fármacos , Hígado/patología , Regeneración Hepática/efectos de los fármacos , Mitosis/efectos de los fármacos
15.
Front Microbiol ; 8: 1150, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28694796

RESUMEN

Gene duplication is one of the major evolutionary mechanisms providing raw material for the generation of genes with new or modified functions. The yeast Saccharomyces cerevisiae originated after an allopolyploidization event, which involved mating between two different ancestral yeast species. ScALT1 and ScALT2 codify proteins with 65% identity, which were proposed to be paralogous alanine transaminases. Further analysis of their physiological role showed that while ScALT1 encodes an alanine transaminase which constitutes the main pathway for alanine biosynthesis and the sole pathway for alanine catabolism, ScAlt2 does not display alanine transaminase activity and is not involved in alanine metabolism. Moreover, phylogenetic studies have suggested that ScALT1 and ScALT2 come from each one of the two parental strains which gave rise to the ancestral hybrid. The present work has been aimed to the understanding of the properties of the ancestral type Lacchancea kluyveri LkALT1 and Kluyveromyces lactis KlALT1, alanine transaminases in order to better understand the ScALT1 and ScALT2 evolutionary history. These ancestral -type species were chosen since they harbor ALT1 genes, which are related to ScALT2. Presented results show that, although LkALT1 and KlALT1 constitute ScALT1 orthologous genes, encoding alanine transaminases, both yeasts display LkAlt1 and KlAlt1 independent alanine transaminase activity and additional unidentified alanine biosynthetic and catabolic pathway(s). Furthermore, phenotypic analysis of null mutants uncovered the fact that KlAlt1 and LkAlt1 have an additional role, not related to alanine metabolism but is necessary to achieve wild type growth rate. Our study shows that the ancestral alanine transaminase function has been retained by the ScALT1 encoded enzyme, which has specialized its catabolic character, while losing the alanine independent role observed in the ancestral type enzymes. The fact that ScAlt2 conserves 64% identity with LkAlt1 and 66% with KlAlt1, suggests that ScAlt2 diversified after the ancestral hybrid was formed. ScALT2 functional diversification resulted in loss of both alanine transaminase activity and the additional alanine-independent LkAlt1 function, since ScALT2 did not complement the Lkalt1Δ phenotype. It can be concluded that LkALT1 and KlLALT1 functional role as alanine transaminases was delegated to ScALT1, while ScALT2 lost this role during diversification.

16.
Acta cir. bras ; Acta cir. bras;32(3): 194-202, Mar. 2017. tab, graf
Artículo en Inglés | LILACS | ID: biblio-837694

RESUMEN

Abstract Purpose: To investigate the effects of lycopene and resveratrol pretreatment on hepatic hyperplasia in partially hepatectomized rats. Methods: The lycopene group and the resveratrol group received 40 mg/kg/day of lycopene or resveratrol, respectively (dissolved in olive oil or in saline solution, respectively) and administered via a gastric tube for 30 days. The partially hepatectomzed (PH) control groups received saline or olive oil via a gastric tube for 30 days, respectively, and the normal control group received no treatment. Liver tissue and intracardiac blood samples were obtained 24, 36 or 48 h after PH. Results: No areas of fibrosis were detected. No significant changes in mitotic index, in the number of apoptosis events or in aspartate aminotransferase and alanine aminotransferase levels were observed. Conclusions: Lycopene and resveratrol pretreatment did not interfere on hepatic hyperplasia in partially hepatectomized rats.


Asunto(s)
Animales , Masculino , Estilbenos/farmacología , Carotenoides/farmacología , Hepatectomía/métodos , Hígado/cirugía , Hígado/efectos de los fármacos , Antioxidantes/farmacología , Aspartato Aminotransferasas/sangre , Factores de Tiempo , Reproducibilidad de los Resultados , Resultado del Tratamiento , Ratas Wistar , Apoptosis/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Alanina Transaminasa/sangre , Hígado/enzimología , Hígado/patología , Regeneración Hepática/efectos de los fármacos , Índice Mitótico
17.
Acta cir. bras. ; 32(3): 194-202, mar. 2017. ilus, ^tab
Artículo en Inglés | VETINDEX | ID: vti-17072

RESUMEN

Purpose: To investigate the effects of lycopene and resveratrol pretreatment on hepatic hyperplasia in partially hepatectomized rats. Methods: The lycopene group and the resveratrol group received 40 mg/kg/day of lycopene or resveratrol, respectively (dissolved in olive oil or in saline solution, respectively) and administered via a gastric tube for 30 days. The partially hepatectomzed (PH) control groups received saline or olive oil via a gastric tube for 30 days, respectively, and the normal control group received no treatment. Liver tissue and intracardiac blood samples were obtained 24, 36 or 48 h after PH. Results: No areas of fibrosis were detected. No significant changes in mitotic index, in the number of apoptosis events or in aspartate aminotransferase and alanine aminotransferase levels were observed. Conclusions: Lycopene and resveratrol pretreatment did not interfere on hepatic hyperplasia in partially hepatectomized rats.(AU)


Asunto(s)
Animales , Masculino , Ratas , Alanina Transaminasa , Hepatectomía , Aspartato Aminotransferasas , Apoptosis , Índice Mitótico , Carotenoides/uso terapéutico , Polifenoles/uso terapéutico , Hígado/irrigación sanguínea , Hígado/lesiones , Hígado/cirugía
18.
Arch. endocrinol. metab. (Online) ; 60(2): 101-107, Apr. 2016. tab, graf
Artículo en Inglés | LILACS | ID: lil-782153

RESUMEN

Objective Thyroid disease affects 6.6% of the general population. The liver is fundamental in metabolizing thyroid hormones, and hepatocytes are often affected in thyroid disease. We aimed to compare clinical and laboratory parameters among thyroid disease patients with alanine aminotransferase (ALT) levels above vs. below the upper tertile. Subjects and methods A retrospective cross-sectional analytical study was conducted in the endocrinology clinic at Polydoro Ernani de São Thiago University Hospital. Patients with thyroid disease between August 2012 and January 2014 were included in the study. Clinical and laboratory parameters were collected from medical records. Results One hundred patients were included, of which 14.0% were male, with a mean age of 49.1 ± 14.4 years. ALT levels ranged from 9 to 90 U/L, and the ALT upper tertile was defined as 0,64 times the upper normal limit (xUNL). Patients with ALT levels above the upper tertile exhibited a higher proportion of systemic arterial hypertension (SAH), a higher mean abdominal circumference and a higher frequency of elevated TSH levels than did patients with ALT levels below the upper tertile. In multivariate analysis, ALT ≥ 0.64 (xUNL) was independently associated with abdominal circumference (odds ratio [OR] = 0.087, 95% confidence interval [CI] 0012-0167, P = 0.022). ALT (xUNL) correlated positively with total cholesterol (r = 0.213, P = 0.042). Conclusions In patients with thyroid diseases, it was observed that those with ALT above the upper tertile are associated with abdominal circumference and ALT levels correlate with total cholesterol.


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Enfermedades de la Tiroides/sangre , Alanina Transaminasa/sangre , Valores de Referencia , Tirotropina/sangre , Índice de Masa Corporal , Colesterol/sangre , Estudios Transversales , Estudios Retrospectivos , Factores de Riesgo , Dislipidemias/sangre , Circunferencia de la Cintura , Hipertensión/sangre , Hepatopatías/sangre
19.
Rev. colomb. gastroenterol ; 30(4): 412-418, oct.-dic. 2015. tab
Artículo en Español | LILACS | ID: lil-772415

RESUMEN

Introducción: la enfermedad celíaca es una enfermedad autoinmune provocada por la ingestión de gluten que afecta aproximadamente al 0,5%-1% de la población mundial. Las señales extraintestinales incluyen elevados niveles de alanina-aminotransferasa (ALT). Objetivo: evaluar los efectos de una dieta libre de gluten en los niveles ALT en pacientes con enfermedad celíaca. Métodos: este estudio transversal se llevó a cabo en la clínica ambulatoria de gastroenterología de un hospital universitario. Resultados: se incluyeron veintiséis pacientes con enfermedad celíaca con edad de 34,1 ± 11,4 años; 15,4% fueron hombres. Los sujetos del estudio tenían un nivel promedio de ALT de 54,6 ± 36,3 (mediana 40,5) U/L. Hubo una mayor proporción de individuos con hepatitis B en el grupo con ALT ≥50 U/L en comparación con sujetos con ALT <50 U/L. Entre los pacientes evaluados después del tratamiento con dieta libre de gluten se observó una reducción significativa de los valores de ALT (36,0 versus 31,0 U/l; p= 0,008). Conclusión: el treinta y cinco por ciento de los pacientes con enfermedad celíaca tenía ALT por encima del tercil superior. Se encontraron niveles más altos de ALT en pacientes con hepatitis viral B y en aquéllos que no se adhirieron a la dieta. Hubo una reducción de aminotransferasas como resultado de una dieta libre de gluten.


Introduction: Celiac disease is an autoimmune disease triggered by ingestion of gluten. It affects approximately 0.5% to 1% of the world population. Extra intestinal manifestations include elevated alanine aminotransferase (ALT) levels. Objective: The objective of this study was to evaluate the effects of a gluten-free diet on ALT levels in patients with celiac disease. Methods: This cross-sectional study was conducted in the gastroenterology outpatient clinic of a university hospital. Results: Twenty-six patients with celiac disease were included. Average patient age was 34.1 ± 11.4 years, and 15.4% of the patients were men. Study subjects had a mean ALT level of 54.6 ± 36.3 U/L (median 40.5). There was a higher proportion of individuals with hepatitis B in the group with ALT ≥ 50 U/L than in the group of subjects with ALT < 50 U/L. Among patients tested after treatment with a gluten-free diet, we observed a significant reduction in ALT values (36.0 vs. 31.0 U/L; P = 0.008). Conclusion: Thirty-five percent of celiac disease patients had ALT levels above the upper tertile. Higher ALT levels were found in patients with viral hepatitis B and in those who do not adhere to the diet. There was a reduction of aminotransferases with a gluten-free diet.


Asunto(s)
Humanos , Masculino , Femenino , Alanina Transaminasa , Enfermedad Celíaca , Dieta Sin Gluten , Transaminasas
20.
Acta cir. bras ; Acta cir. bras;28(1): 55-58, jan. 2013. tab
Artículo en Inglés | LILACS | ID: lil-662348

RESUMEN

PURPOSE: To analyze the intraoperative and immediate postoperative biochemical parameters of patients submitted to orthotopic liver transplantation. METHODS: Forty four consecutive orthotopic liver transplants performed from October 2009 to December 2010 were analyzed. The patients (38 male and eight female) were divided into two groups: group A, survivors, and group B, non-survivors. Fifty percent of group A patients were Chid-Pugh C, 40% Chid-Pugh B and 10% Chid-Pugh A. In group B, 52% of the patients were Chid-Pugh C, 41% Chid-Pugh B, and 17% Chid-Pugh A. All orthotopic liver transplants were performed by the piggy-back technique without a portacaval shunt in an anhepatic phase. ALT, AST, LDH and lactate levels were determined preoperatively, at five, 60 minutes after arterial revascularization of the graft and 24 and 48 hours after the end of the surgery.( or: after the surgery was finished). RESULTS: There were no preoperative clinical differences (Child and Meld) between the two groups. The times of warm and hypothermal ischemia were similar for both groups (p>0.05). Serum aminotransferases levels at five and 60 minutes after arterial revascularization of the graft were similar (p>0.05) for both groups, as also were lactate levels at the time points studied. There was no significant difference in Δ lactate between groups at any time point studied (p>0.05). No significant difference was observed between groups during the first 24 and 48 hours after surgery (p>0.05). CONCLUSION: No significant difference in any of the parameters studied was observed between groups. Under the conditions of the present study and considering the parameters evaluated, no direct relationship was detected between the intraoperative situation and the type of evolution of the patients of the two groups studied.


Asunto(s)
Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Trasplante de Hígado/estadística & datos numéricos , Pulmón/química , Alanina Transaminasa/sangre , Aspartato Aminotransferasas/sangre , Hospitales Universitarios , Periodo Intraoperatorio , L-Lactato Deshidrogenasa/sangre , Ácido Láctico/sangre , Periodo Posoperatorio , Estudios Prospectivos , Distribución por Sexo , Análisis de Supervivencia , Factores de Tiempo , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA